{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:36:40Z","timestamp":1786981000832,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10620-022-07562-0","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:18:59Z","timestamp":1655896739000},"page":"1006-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Crohn\u2019s Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-1700","authenticated-orcid":false,"given":"Manik","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopanandan","family":"Parthasarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Nowacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthvik","family":"Padival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Click","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"7562_CR1","first-page":"11","volume":"15","author":"Z Younossi","year":"2017","unstructured":"Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Publ Gr. 2017;15:11\u201320.","journal-title":"Nat Publ Gr."},{"key":"7562_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1479","volume":"4","author":"G Parthasarathy","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholicsteatohepatitis: an overview. Hepatol Commun. 2020;4:478\u2013492.","journal-title":"Hepatol Commun."},{"key":"7562_CR3","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020;158:1611-1625.e12.","journal-title":"Gastroenterology"},{"key":"7562_CR4","first-page":"643","volume":"4","author":"M Argollo","year":"2019","unstructured":"Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J-F, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. LancetGastroenterol Hepatol. 2019;4:643\u201354.","journal-title":"LancetGastroenterol Hepatol."},{"key":"7562_CR5","first-page":"969","volume":"8","author":"M Sun","year":"2015","unstructured":"Sun M, He C, Cong Y, Liu Z. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. MucosalImmunol. 2015;8:969\u2013978.","journal-title":"MucosalImmunol."},{"key":"7562_CR6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ibd\/izz043","volume":"25","author":"ZY Zou","year":"2019","unstructured":"Zou ZY, Shen B, Fan JG. Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. Inflamm BowelDis. 2019;25:1764\u20131772.","journal-title":"Inflamm BowelDis."},{"key":"7562_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/ibd\/izaa189","volume":"27","author":"A Lin","year":"2020","unstructured":"Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematicreview and meta-analysis. Inflamm BowelDis. 2020;27:947\u2013955.","journal-title":"Inflamm BowelDis."},{"key":"7562_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s Disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol."},{"key":"7562_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol."},{"key":"7562_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313\u20131321.","journal-title":"Hepatology"},{"key":"7562_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","volume":"69","author":"R Loomba","year":"2020","unstructured":"Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343\u20131352.","journal-title":"Gut"},{"key":"7562_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837.","journal-title":"Biometrics"},{"key":"7562_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cld.685","volume":"11","author":"P Hartmann","year":"2018","unstructured":"Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis. 2018;11:11\u20135.","journal-title":"Clin Liver Dis."},{"key":"7562_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603926","author":"C Peng","year":"2020","unstructured":"Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-alcoholicsteatohepatitis: a review of its mechanism models and medical treatments. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.603926.","journal-title":"Front Pharmacol"},{"key":"7562_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/hepr.12658","volume":"46","author":"Y Akazawa","year":"2016","unstructured":"Akazawa Y, Nakao K. Lipotoxicity pathways intersect in hepatocytes: endoplasmic reticulum stress, c-Jun N-terminal kinase-1, and death receptors. Hepatol Res. 2016;46:977\u2013984.","journal-title":"Hepatol Res."},{"key":"7562_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/CS20150405","volume":"130","author":"S Rolla","year":"2016","unstructured":"Rolla S, Alchera E, Imarisio C et al. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin Sci. 2016;130:193\u2013203.","journal-title":"Clin Sci."},{"key":"7562_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0168-8278(99)80010-5","volume":"30","author":"C Hellerbrand","year":"1999","unstructured":"Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGF\u03b21 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77\u201387.","journal-title":"J Hepatol."},{"key":"7562_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"7562_CR19","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1053\/j.gastro.2009.08.042","volume":"137","author":"MA Hildebrandt","year":"2009","unstructured":"Hildebrandt MA, Hoffmann C, Sherrill-Mix SA et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009;137:1716-1724.e2.","journal-title":"Gastroenterology"},{"key":"7562_CR20","doi-asserted-by":"publisher","first-page":"11365","DOI":"10.1038\/s41598-018-29735-6","volume":"8","author":"Y Ogawa","year":"2018","unstructured":"Ogawa Y, Imajo K, Honda Y et al. Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. Sci Rep. 2018;8:11365.","journal-title":"Sci Rep."},{"key":"7562_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00154","author":"T Zietek","year":"2016","unstructured":"Zietek T, Rath E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1. Front Immunol. 2016. https:\/\/doi.org\/10.3389\/fimmu.2016.00154.","journal-title":"Front Immunol."},{"key":"7562_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/gutjnl-2015-310283","volume":"66","author":"A Pars\u00e9us","year":"2017","unstructured":"Pars\u00e9us A, Sommer N, Sommer F et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 2017;66:429\u2013437.","journal-title":"Gut"},{"key":"7562_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.606298","author":"J Sankarasubramanian","year":"2020","unstructured":"Sankarasubramanian J, Ahmad R, Avuthu N, Singh AB, Guda C. Gut Microbiota and metabolic specificity in ulcerative colitis and Crohn\u2019s disease. Front Med. 2020. https:\/\/doi.org\/10.3389\/fmed.2020.606298.","journal-title":"Front Med."},{"key":"7562_CR24","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci. 2008;105:16731\u201316736.","journal-title":"Proc Natl Acad Sci."},{"key":"7562_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01226","author":"R Mart\u00edn","year":"2017","unstructured":"Mart\u00edn R, Miquel S, Benevides L et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol. 2017. https:\/\/doi.org\/10.3389\/fmicb.2017.01226.","journal-title":"Front Microbiol."},{"key":"7562_CR26","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","volume":"7","author":"N Hossain","year":"2009","unstructured":"Hossain N, Afendy A, Stepanova M et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224\u20131229.e2.","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07562-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T01:13:36Z","timestamp":1678670016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07562-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["7562"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07562-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Benjamin Click reports consulting fees for TARGET-RWE, speakers bureau for Takeda. Florian Rieder reports consulting and advisory boards for Adnovate, Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene\/BMS, CDISC, Cowen, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, 89Bio and research funding from the NIH, Helmsley Charitable Trust, Crohn\u2019s and Colitis Foundation, UCB, Pliant, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Morphic, Kenneth Rainin Foundation. Benjamin Cohen receives financial support for advisory boards and consultant for Abbvie, Celgene-Bristol Myers Squibb, Lilly, Pfizer, Sublimity Therapeutics, Takeda, TARGET RWE; CME Companies: Cornerstones, Vindico; Speaking: Abbvie. Other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}